PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026Scientific Reports0 citationsOpen Access

The role of CUEDC1 in suppressing JAK1/STAT3 signaling pathway in esophageal cancer

ZLZhuo LiAnhui Medical UniversityZPZhipeng PanAnhui Medical UniversityXSXing SuAnhui Medical University

Key Points

  • The aim is to clarify how CUEDC1 regulates the JAK1/STAT3 signaling pathway in esophageal cancer.
  • Assessment of CUEDC1 expression levels in esophageal cancer cells
  • Analysis of JAK1/STAT3 pathway activity in cells with manipulated CUEDC1 levels
  • Ubiquitination and degradation pathways evaluation for STAT3
  • Correlation of CUEDC1 expression with survival rates and clinical outcomes
  • Overexpression of CUEDC1 decreased JAK1/STAT3 signaling activity
  • Reduced cell proliferation, migration, and invasion capabilities observed with increased CUEDC1
  • Direct binding of CUEDC1 to STAT3 facilitates its ubiquitination
  • Lower STAT3 protein levels correlate with higher CUEDC1 expression

Abstract

CUE domain containing protein 1 (CUEDC1) is implicated in tumor progression; however, its specific role in esophageal cancer (ESCA) remains unclear. In esophageal cancer, the expression of CUEDC1 is notably low, which correlates with reduced survival rates and adverse clinical outcomes. Overexpression of CUEDC1 results in decreased activity of the JAK1/STAT3 signaling pathway in cells, consequently diminishing their proliferation, migration, and invasion capabilities. This mechanism operates through the direct binding of CUEDC1 to STAT3, facilitating its ubiquitination and triggering the ubiquitin-proteasome degradation pathway, ultimately leading to a significant reduction in intracellular STAT3 levels. This study suggests that CUEDC1 can reduce intracellular STAT3 protein levels, thereby inhibiting JAK1/STAT3 signaling transduction and suppressing the progression of ESCA. This study aims to elucidate the regulatory mechanism of CUEDC1 on STAT3, which will enhance our understanding of the regulatory pathways involved in the treatment of esophageal cancer and potentially other tumors. Future breakthroughs and innovations may emerge from molecular research and development targeting this pathway.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69cf5e995a333a821460d02fhttps://doi.org/10.1038/s41598-026-46681-w
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Exploring Potential Biomarkers in Oesophageal Cancer: A Comprehensive Analysis2024 · 8 citations
  2. 2Ubiquitin ligases: cell-cycle control and cancer2006 · 1,449 citations
  3. 3TRIM27 mediates STAT3 activation at retromer-positive structures to promote colitis and colitis-associated carcinogenesis2018 · 102 citations
  4. 4Anti-Inflammatory Activity of Bone Morphogenetic Protein Signaling Pathways in Stomachs of Mice2014 · 56 citations
  5. 5STATs and Gene Regulation1997 · 4,023 citations